XBiotech Inc. (4XB)
XFRA 
Summary
4XB Chart
The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT). Investors who purchased XBiotech securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XBIT.
XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ("XBiotech" or "the Company") (NASDAQ:XBIT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
XBiotech Inc. (4XB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has XBiotech Inc. ever had a stock split?
XBiotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sushma Shivaswamy CEO | XFRA Exchange | CA98400H1029 ISIN |
| US Country | 92 Employees | 23 Jul 2021 Last Dividend | - Last Split | 15 Apr 2015 IPO Date |
Overview
XBiotech Inc. is a pioneering biopharmaceutical company engaged in the discovery, development, and commercialization of True Human monoclonal antibodies aimed at treating a variety of diseases. Founded in 2005 and based in Austin, Texas, XBiotech focuses on a patient-centric approach to develop therapies that harness the body's natural immune response. The company is dedicated to advancing a broad pipeline of product candidates targeting both inflammatory and infectious diseases. With a commitment to innovation and excellence, XBiotech strives to address some of the most challenging medical conditions with cutting-edge treatments designed to improve patient outcomes.
Products and Services
- True Human Monoclonal Antibodies: XBiotech specializes in the discovery and development of True Human monoclonal antibodies. Unlike traditional monoclonal antibodies, which are often developed using mouse models, True Human antibodies are derived from humans, making them potentially more effective and less likely to cause unwanted immune responses. These antibodies are developed to target and neutralize specific proteins involved in the pathogenesis of various diseases, offering hope for more effective treatments.
- Interleukin-1 Alpha Therapies: The company is pioneering the development of therapies targeting interleukin-1 alpha (IL-1α), a key mediator of inflammation and immune response. These therapies are being researched for their potential to treat a wide range of medical conditions, including cancer, stroke, heart attack, and arthritis. By targeting IL-1α, XBiotech aims to modulate the body's inflammatory response and provide therapeutic benefits in diseases characterized by excessive or uncontrolled inflammation.
